Key facts
- It has raised $56.5M; the latest was Grant ($5.0M) in May 2025.
- Notable investors include Bpifrance, Khosla Ventures, European Commission, Agoranov, CARB-X — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Eligo Bioscience
- ·The full record, as it builds
Funding rounds
No funding rounds for Eligo Bioscience are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Eligo Bioscience
Developer of antibiotics designed to treat microbiome precision and bacteria-associated diseases. The company's antibiotics combine sequencing systems with engineered phage capsids, to develop antimicrobials that are used to eradicate resistant pathogens or virulent bacteria within the human microbiome, enabling pharmaceutical companies to make medicines from pathogen-resistant antimicrobials.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2014
- Employees
- 47
- Website
- eligo.bio/
- Ownership
- Privately Held (backing)
Eligo Bioscience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Eligo Bioscience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Eligo Bioscience in its N-PORT filings yet. We sweep new filings monthly.